vs

Side-by-side financial comparison of Beneficient (BENF) and Arcus Biosciences, Inc. (RCUS). Click either name above to swap in a different company.

Beneficient is the larger business by last-quarter revenue ($18.7M vs $11.0M, roughly 1.7× Arcus Biosciences, Inc.). Beneficient runs the higher net margin — 106.7% vs -963.6%, a 1070.3% gap on every dollar of revenue. On growth, Beneficient posted the faster year-over-year revenue change (322.5% vs -52.2%).

Beneficient is a financial services firm specializing in alternative asset liquidity solutions. It offers tailored options for holders of illiquid alternative investments including private equity, hedge fund stakes, and real assets, serving institutional investors, high-net-worth individuals, and family offices primarily in North America.

Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.

BENF vs RCUS — Head-to-Head

Bigger by revenue
BENF
BENF
1.7× larger
BENF
$18.7M
$11.0M
RCUS
Growing faster (revenue YoY)
BENF
BENF
+374.7% gap
BENF
322.5%
-52.2%
RCUS
Higher net margin
BENF
BENF
1070.3% more per $
BENF
106.7%
-963.6%
RCUS

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
BENF
BENF
RCUS
RCUS
Revenue
$18.7M
$11.0M
Net Profit
$19.9M
$-106.0M
Gross Margin
Operating Margin
21.1%
-1036.4%
Net Margin
106.7%
-963.6%
Revenue YoY
322.5%
-52.2%
Net Profit YoY
330.5%
-12.8%
EPS (diluted)
$-0.88

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BENF
BENF
RCUS
RCUS
Q4 25
$18.7M
$11.0M
Q3 25
$-2.8M
$6.0M
Q2 25
$-12.6M
$8.0M
Q1 25
$-31.0M
$8.0M
Q4 24
$4.4M
$23.0M
Q3 24
$8.6M
$7.0M
Q2 24
$10.0M
$11.0M
Q1 24
$10.0M
Net Profit
BENF
BENF
RCUS
RCUS
Q4 25
$19.9M
$-106.0M
Q3 25
$-17.9M
$-135.0M
Q2 25
$-92.6M
$0
Q1 25
$-44.6M
$-112.0M
Q4 24
$-8.6M
$-94.0M
Q3 24
$9.7M
$-92.0M
Q2 24
$44.3M
$-93.0M
Q1 24
$-4.0M
Operating Margin
BENF
BENF
RCUS
RCUS
Q4 25
21.1%
-1036.4%
Q3 25
646.5%
-2366.7%
Q2 25
734.0%
-100.0%
Q1 25
146.3%
-1525.0%
Q4 24
-215.3%
-447.8%
Q3 24
-160.2%
-1500.0%
Q2 24
-963.6%
Q1 24
-160.0%
Net Margin
BENF
BENF
RCUS
RCUS
Q4 25
106.7%
-963.6%
Q3 25
648.1%
-2250.0%
Q2 25
734.0%
Q1 25
144.1%
-1400.0%
Q4 24
-195.5%
-408.7%
Q3 24
113.9%
-1314.3%
Q2 24
441.1%
-845.5%
Q1 24
-40.0%
EPS (diluted)
BENF
BENF
RCUS
RCUS
Q4 25
$-0.88
Q3 25
$-1.27
Q2 25
$0.00
Q1 25
$-1.14
Q4 24
$-1.07
Q3 24
$-1.00
Q2 24
$-1.02
Q1 24
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BENF
BENF
RCUS
RCUS
Cash + ST InvestmentsLiquidity on hand
$7.9M
$222.0M
Total DebtLower is stronger
$99.0M
Stockholders' EquityBook value
$-128.6M
$631.0M
Total Assets
$337.9M
$1.1B
Debt / EquityLower = less leverage
0.16×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BENF
BENF
RCUS
RCUS
Q4 25
$7.9M
$222.0M
Q3 25
$4.9M
$238.0M
Q2 25
$7.6M
$248.0M
Q1 25
$1.3M
$192.0M
Q4 24
$4.1M
$150.0M
Q3 24
$4.5M
$201.0M
Q2 24
$4.4M
$156.0M
Q1 24
$185.0M
Total Debt
BENF
BENF
RCUS
RCUS
Q4 25
$99.0M
Q3 25
$98.0M
Q2 25
$97.0M
Q1 25
$48.0M
Q4 24
$48.0M
Q3 24
$47.0M
Q2 24
Q1 24
Stockholders' Equity
BENF
BENF
RCUS
RCUS
Q4 25
$-128.6M
$631.0M
Q3 25
$-142.8M
$436.0M
Q2 25
$-120.4M
$549.0M
Q1 25
$-34.9M
$531.0M
Q4 24
$14.3M
$485.0M
Q3 24
$-13.2M
$565.0M
Q2 24
$-148.3M
$635.0M
Q1 24
$707.0M
Total Assets
BENF
BENF
RCUS
RCUS
Q4 25
$337.9M
$1.1B
Q3 25
$316.2M
$974.0M
Q2 25
$334.5M
$1.1B
Q1 25
$354.9M
$1.2B
Q4 24
$400.0M
$1.1B
Q3 24
$368.8M
$1.3B
Q2 24
$361.3M
$1.2B
Q1 24
$1.3B
Debt / Equity
BENF
BENF
RCUS
RCUS
Q4 25
0.16×
Q3 25
0.22×
Q2 25
0.18×
Q1 25
0.09×
Q4 24
0.10×
Q3 24
0.08×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BENF
BENF
RCUS
RCUS
Operating Cash FlowLast quarter
$-9.4M
$-120.0M
Free Cash FlowOCF − Capex
$-121.0M
FCF MarginFCF / Revenue
-1100.0%
Capex IntensityCapex / Revenue
0.0%
9.1%
Cash ConversionOCF / Net Profit
-0.47×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BENF
BENF
RCUS
RCUS
Q4 25
$-9.4M
$-120.0M
Q3 25
$-14.5M
$-97.0M
Q2 25
$-10.8M
$-133.0M
Q1 25
$-37.7M
$-132.0M
Q4 24
$-10.0M
$-100.0M
Q3 24
$-8.6M
$26.0M
Q2 24
$-10.6M
$-94.0M
Q1 24
$-2.0M
Free Cash Flow
BENF
BENF
RCUS
RCUS
Q4 25
$-121.0M
Q3 25
Q2 25
$-10.9M
Q1 25
$-38.8M
$-133.0M
Q4 24
$-10.0M
$-101.0M
Q3 24
$-8.9M
$25.0M
Q2 24
$-11.3M
Q1 24
$-6.0M
FCF Margin
BENF
BENF
RCUS
RCUS
Q4 25
-1100.0%
Q3 25
Q2 25
86.6%
Q1 25
125.3%
-1662.5%
Q4 24
-227.2%
-439.1%
Q3 24
-103.7%
357.1%
Q2 24
-112.6%
Q1 24
-60.0%
Capex Intensity
BENF
BENF
RCUS
RCUS
Q4 25
0.0%
9.1%
Q3 25
0.0%
0.0%
Q2 25
-0.8%
0.0%
Q1 25
-3.5%
12.5%
Q4 24
1.0%
4.3%
Q3 24
3.1%
14.3%
Q2 24
6.6%
0.0%
Q1 24
40.0%
Cash Conversion
BENF
BENF
RCUS
RCUS
Q4 25
-0.47×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
-0.88×
Q2 24
-0.24×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BENF
BENF

Ben Liquidity$8.2M44%
Other$7.6M41%
Ben Custody$2.9M16%

RCUS
RCUS

Other$5.0M45%
Other Collaboration Revenue$4.0M36%
Access Rights And Option Continuation Periods$2.0M18%

Related Comparisons